Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents-Reference-Cited by-同舟云学术

Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

Published:2019-10-01 Issue:2 Volume:61 Page:397-408
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zeidan Amer M.¹²,Hu Xin²^ORCID,Zhu Weiwei²,Stahl Maximilian¹,Wang Rong²³,Huntington Scott F.¹²,Giri Smith¹²,Bewersdorf Jan Philipp¹^ORCID,Podoltsev Nikolai A.¹²,Gore Steven D.¹²,Ma Xiaomei²³,Davidoff Amy J.²⁴

Affiliation:

1. Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA;

2. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;

3. Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, CT, USA;

4. Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1663423

Reference26 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

2. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials

3. Emerging biological therapies for the treatment of myelodysplastic syndromes

4. Comorbidity Measures for Use with Administrative Data

5. Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Yisui granule ((sic)) on myelodysplastic syndromes in SKM-1 mouse xenograft model through suppressing Wnt/β-catenin signaling pathway;J TRADIT CHIN MED;2024

2. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: The Kyoto Conditional Survival Scoring System;Oncology Letters;2023-12-18

3. Are We Ready For “Triplet” Therapy in Higher-Risk MDS?;Clinical Hematology International;2023-11-03

4. Overview of the Management of Higher-Risk Myelodysplastic Syndromes;The Cancer Journal;2023-05

5. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia;Haematologica;2023-04-13